title: [Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy].
abstract: OBJECTIVE
  Chronic hepatitis B virus (HBV) infection increases the prevalence of liver damage and related death of malignant tumor patients. This study was to investigate the prevalence of liver damage and clinical results in lymphoma patients with chronic HBV infection after standard chemotherapy, and assess high risk factors associated with liver damage for better guidance in clinic.
  
  
  METHODS
  Records of 116 lymphoma patients with chronic HBV infection, treated with standard chemotherapy from Jan. 1985 to Jan. 2002 in Cancer Center of Sun Yat-sen University, were reviewed to analyze the prevalence of liver damage, clinical results, and related high risk factors.
  
  
  RESULTS
  Of the 116 patients, 60 (51.7%) suffered liver damage. According to WHO criteria of liver toxicity, 4 (3.4%) were in grade I, 14 (12.1%) in grade II, 15 (12.9%) in grade III, and 27 (23.3%) in grade IV. After treatment for liver damage, 11 (9.5%) patients completed chemotherapy without delay, 27(23.3%) completed chemotherapy with delay of more than 8 days, 16 (13.8%) terminated chemotherapy, 6 (5.2%) died. Logistic multivariate analysis showed that steroid was a high risk factor of liver damage after chemotherapy.
  
  
  CONCLUSIONS
  The prevalence of liver damage is high in lymphoma patients with chronic HBV infection after standard chemotherapy, which led to treatment delay or discontinue, even death. Steroid is a high risk of liver damage.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, P. R. China. yuhongli@163.net
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Li
authors.forename: Yi-Fu
authors.initials: YF
authors.lastname: He
authors.forename: Feng-Hua
authors.initials: FH
authors.lastname: Wang
authors.forename: Xu-Bin
authors.initials: XB
authors.lastname: Lin
authors.forename: Zhong-Jun
authors.initials: ZJ
authors.lastname: Xia
authors.forename: Xiao-Fei
authors.initials: XF
authors.lastname: Sun
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
authors.forename: Hui-Qiang
authors.initials: HQ
authors.lastname: Huang
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Xu
authors.forename: Wen-Qi
authors.initials: WQ
authors.lastname: Jiang
authors.forename: Zhong-Zhen
authors.initials: ZZ
authors.lastname: Guan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D019694:Hepatitis B, Chronic / Q000209:etiology* / Q000473:pathology; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008099:Liver / Q000473:pathology*; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D013256:Steroids / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D013256:Steroids; D004317:Doxorubicin